USPTO Patent Application: Solid Dosage Form of Antiviral Nucleoside

ChangeBridge: Patent Apps - Pharma (A61K)

Published December 11th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a new patent application from Merck Sharp & Dohme LLC for an oral dosage form of a small molecule antiviral nucleoside. The application details specific formulation components and pellet size requirements for the antiviral drug.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083767A1) filed by Merck Sharp & Dohme LLC. It describes a solid oral dosage form for an antiviral nucleoside, specifying the inclusion of compression aids, glidants, lubricants, and disintegrants. A key feature is that the oral dosage form is a pellet with a diameter of 4.0 mm or less.

This is a patent application, not a regulatory rule or guidance. It does not impose any immediate compliance obligations on pharmaceutical companies. However, it represents a potential future intellectual property asset for Merck Sharp & Dohme LLC related to antiviral drug formulations. Companies involved in antiviral drug development should be aware of this filing as it may impact future market exclusivity or licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

SOLID DOSAGE FORM OF A SMALL MOLECULE ANTIVIRAL AND USES THEREOF

Application US20260083767A1 Kind: A1 Mar 26, 2026

Assignee

Merck Sharp & Dohme LLC

Inventors

Nicole Devitt, Brandon G. Gerberich, Prapti Kafle, Michael Lowinger, Grace A. Okoh, Sanjaykumar Patel, Somya Singh, James S. Tarabokija, Yuejie Zhao

Abstract

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.